AstraZeneca invests $30M to modernize Wuxi drug plant, expand capacity

AstraZeneca announced a ~$30M investment to expand and modernize its Wuxi, Jiangsu industrial and logistics base, adding manufacturing capacity and development lines for next-generation cardiovascular drugs. The move signals continued foreign pharma commitment to China's market despite broader geopolitical friction. Impact is company-specific and modest in scale, with no macro-directional market signal.